Health-care companies rose amid ongoing enthusiasm about obesity drugs.
Shares of Danish drugmaker Novo Nordisk rose by more than 3% as traders bet demand would continue to rise for the company's Ozempic drug. Eli Lilly, whose Mounjaro product is set to be a key Ozempic rival, also rose.
Physician-office landlords Healthpeak Properties and Physicians Realty Trust agreed to an all-stock merger valued at $21 billion.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
10-30-23 1749ET
